Peregrine Pharmaceuticals (NASDAQ:PPHM)

CAPS Rating: 2 out of 5

A biopharmaceutical company with a portfolio of clinical stage and pre-clinical product candidates using monoclonal antibodies for the treatment of cancer and viral diseases.

Recs

0
Player Avatar JPlace09 (22.06) Submitted: 11/7/2013 9:54:36 PM : Outperform Start Price: $1.23 PPHM Score: +21.05

Despite the poorly run early stage trials, I think they might have a winner in Bavituximab. We'll see.

Featured Broker Partners


Advertisement